Lipigon initially focuses on rare diseases that may qualify for orphan drug status as well as niche indications. This strategy enables faster market access and cost-effective development while offering the potential for market exclusivity and attractive pricing.

Lipigon manages three projects with unique mechanisms of action, each holding potential for broader indications.

The research portfolio mainly focuses on lipid management, with one exception: Project 4, which targets the treatment and prevention of lung injuries related to Community Acquired Pneumonia (CAP).

Lipigon's most advanced project, Lipisense® (P1), is in the clinical phase and is an RNA-based investigational drug designed to reduce triglyceride levels in patients' blood.